Genome & Co. receives FDA IND clearance for Anti-cancer Microbiome Therapeutics

Genome & Co. is a clinical stage biotechnology company based in South Korea that focuses on discovering and developing the next waves of innovative therapeutics in immuno-oncology through diverse modalities of microbiome, novel target immune checkpoint inhibitors and fusion proteins to fulfill the unmet needs of cancer patients.

[Choi Moon Hee, Business Korea]

Genome & Co. (KONEX: 314130), a Korean biotechnology company developing innovative therapeutics in immune-oncology, announced on April 20 that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for GEN-001 for combination treatment with avelumab (BAVENCIO®) in patients with solid cancers.

기사 전문보기

No comments

    댓글은 닫혔습니다.